Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Rejman observed that "You will recall that in summary the Department feels that there is no justification for routine use of recombinant Factor VIII in patients with haemophilia".

  • Read more about Dr Rejman observed that "You will recall that in summary the Department feels that there is no justification for routine use of recombinant Factor VIII in patients with haemophilia".

Draft briefing for an answer to a parliamentary question which arose in relation to the imposition of VAT on recombinant.

  • Read more about Draft briefing for an answer to a parliamentary question which arose in relation to the imposition of VAT on recombinant.

Dr Savidge stated that market trends in Europe, and North America showed that plasma derived Factor 8 was rapidly being phased out from clinical use in favour of recombinant.

  • Read more about Dr Savidge stated that market trends in Europe, and North America showed that plasma derived Factor 8 was rapidly being phased out from clinical use in favour of recombinant.

Dr Savidge's view on behalf of the Recombinant Factor VIII Users' Group was that the cheaper high purity plasma-derived Factor 8 was substantially contaminated by parvovirus B19. Recombinant Factor 8 was not.

  • Read more about Dr Savidge's view on behalf of the Recombinant Factor VIII Users' Group was that the cheaper high purity plasma-derived Factor 8 was substantially contaminated by parvovirus B19. Recombinant Factor 8 was not.

Dr Savidge did not agree with Kenneth Clarke's comments concerning the comparative safety of the recombinant product.

  • Read more about Dr Savidge did not agree with Kenneth Clarke's comments concerning the comparative safety of the recombinant product.

Dr Rejman wrote: "there is no evidence that recombinant Factor VIII is any safer than plasma derived Factor VIII at the present time. You will be aware that recombinant Factor VIII contains plasma derived albumin as a carrier."

  • Read more about Dr Rejman wrote: "there is no evidence that recombinant Factor VIII is any safer than plasma derived Factor VIII at the present time. You will be aware that recombinant Factor VIII contains plasma derived albumin as a carrier."

Dr Metters made the point that recombinant had a risk, namely, that of being combined with albumin.

  • Read more about Dr Metters made the point that recombinant had a risk, namely, that of being combined with albumin.

Kenneth Clarke stated the treatment of patients with recombinant Factor VIII, which contains human serum albumin as a stabiliser, was not without risk.

  • Read more about Kenneth Clarke stated the treatment of patients with recombinant Factor VIII, which contains human serum albumin as a stabiliser, was not without risk.

Fax from HM Customs and Excise to Dr Rejman regarding Recombinant VAT and Factor VIII.

  • Read more about Fax from HM Customs and Excise to Dr Rejman regarding Recombinant VAT and Factor VIII.

Dr Savidge sent a letter to Kenneth Clarke regarding Recombinant Factor VIII and VAT.

  • Read more about Dr Savidge sent a letter to Kenneth Clarke regarding Recombinant Factor VIII and VAT.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 183
  • Page 184
  • Page 185
  • Page 186
  • Current page 187
  • Page 188
  • Page 189
  • Page 190
  • Page 191
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.